Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails ...
Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA-approved ...
Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the pivotal ...
PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization ...
Beremagene geperpavec, or B-VEC, is a topical gene therapy that showed promise in early trials of dystrophic epidermolysis bullosa, but additional data were needed. New findings from a phase 3 trial ...
(RTTNews) - Abeona Therapeutics Inc. (ABEO) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN, the first cell-based gene therapy for the treatment of wounds in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results